![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Sanofi-Aventis |
---|---|
Information provided by: | Sanofi-Aventis |
ClinicalTrials.gov Identifier: | NCT00443612 |
Primary:
Secondary:
Condition | Intervention | Phase |
---|---|---|
Hypertension |
Drug: Irbesartan/Hydrochlorothiazide Drug: Irbesartan |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Crossover Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Open Label, Cross-Over Comparative Study of Irbesartan/Hydrochlorothiazide and Irbesartan in the Treatment of Mild to Moderate Hypertension |
Enrollment: | 60 |
Study Start Date: | September 2006 |
Primary Completion Date: | October 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
|
Drug: Irbesartan/Hydrochlorothiazide
Administration of irbesartan 150 mg/day + hydrochlorothiazide 12.5 mg
Drug: Irbesartan
Administration of irbesartan 150 mg/day
|
2: Experimental
|
Drug: Irbesartan/Hydrochlorothiazide
Administration of irbesartan 150 mg/day + hydrochlorothiazide 12.5 mg
Drug: Irbesartan
Administration of irbesartan 150 mg/day
|
Ages Eligible for Study: | 20 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Patients with mild to moderate hypertension with office diastolic BP (DBP) 90-109 mmHg and/or systolic BP (SBP) 140-179 mmHg before entering each treatment
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Responsible Party: | sanofi-aventis ( Medical Affairs Study Director ) |
Study ID Numbers: | IRBEH_L_00702 |
Study First Received: | March 5, 2007 |
Last Updated: | November 6, 2008 |
ClinicalTrials.gov Identifier: | NCT00443612 |
Health Authority: | Taiwan: Department of Health |
Irbesartan Vascular Diseases Angiotensin II Hydrochlorothiazide Hypertension |
Angiotensin II Type 1 Receptor Blockers Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Natriuretic Agents Therapeutic Uses Sodium Chloride Symporter Inhibitors |
Physiological Effects of Drugs Diuretics Cardiovascular Diseases Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |